| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2016 | 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC) | Jenkins S; CHIH-HSIN YANG ; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. | Journal of Thoracic Oncology | 16 | 16 | |
| 2016 | 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC | Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG ; Jänne P. | Journal of Thoracic Oncology | 9 | 8 | |
| 2016 | 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial | Ahn M.-J; CHIH-HSIN YANG ; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. | Journal of Thoracic Oncology | 213 | 179 | |
| 2016 | 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) | Schuler M; CHIH-HSIN YANG ; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. | Journal of Thoracic Oncology | 2 | 1 | |
| 2009 | 14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival | KENG-HSUEH LAN | Cancer Research | 157 | 156 | |
| 2016 | 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations | Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG ; Mok T; Kim M; Paz-Ares L. | Journal of Thoracic Oncology | 2 | 2 | |
| 2019 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer | Borghaei H; Langer C.J; Gadgeel S; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG ; Gubens M; Sequist L.V; Awad M.M; Fiore J; Saraf S; Keller S.M; Gandhi L. | Journal of Thoracic Oncology | 149 | 136 | |
| 2012 | 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells | KENG-HSUEH LAN | Biochemical and Biophysical Research Communications | 4 | 4 | |
| 2013 | A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth | KENG-HSUEH LAN | Biochemical and Biophysical Research Communications | 14 | 14 | |
| 2013 | A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer | YU-LIN LIN | British Journal of Cancer | 137 | 122 | |
| 2015 | A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results. | Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil | J. Clin. Oncol. | | | |
| 2020 | Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery | Cho W.-R.; Hung C.-H.; Chen C.-H.; Lin C.-C.; Wang C.-C.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen K.-D.; YU-CHIEH TSAI ; Hu T.-H.; Tsai M.-C. | Scientific Reports | 13 | 13 | |
| 2022 | An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy (vol 46, 101582, 2022) | S.-JA TSENG ; Kempson, IM; Liao, ZX; Ho, YC; Yang, PC | NANO TODAY | 0 | 0 | |
| 2013 | Actin depolymerization under force is governed by lysine 113:glutamic acid 195-mediated catch-slip bonds | Lee, Cho-yin; Lou, Jizhong; Wen, Kuo-kuang; McKane, Melissa; Eskin, Suzanne G.; Ono, Shoichiro; Chien, Shu; Rubenstein, Peter A.; Zhu, Cheng; McIntire, Larry V. | Proceedings of the National Academy of Sciences | 60 | 61 | |
| 2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 146 | 140 | |
| 2011 | Activation of Checkpoint Kinase 2 (Chk2) Contributes to the Antitumour Synergy between Igf1 Receptor Kinase Inhibitor Nvp-Aew541 and Sunitinib in Hepatocellular Carcinoma | OU, DA-LIANG; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII | EUROPEAN JOURNAL OF CANCER | | | |
| 2011 | Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells | Chen, KF; Chen, HL; Tai, WT; Feng, WC; Hsu, CH; Chen, PJ; Cheng, AL | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | | | |
| 2011 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells | Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU ; PEI-JER CHEN ; ANN-LII CHENG | Journal of Pharmacology and Experimental Therapeutics | 252 | 247 | |
| 2004 | Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers | KENG-HSUEH LAN | Clinical Cancer Research | 277 | 255 | |
| 2021 | Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC | BIN-CHI LIAO ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 0 | 0 | |
